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Objectives This study investigated the impact of adding novel elements to models predicting in-hospital mortality after per-
cutaneous coronary interventions (PCIs).
Background Massachusetts mandated public reporting of hospital-specific PCI mortality in 2003. In 2006, a physician advi-
sory group recommended adding to the prediction models 3 attributes not collected by the National Cardiovas-
cular Data Registry instrument. These “compassionate use” (CU) features included coma on presentation, active
hemodynamic support during PCI, and cardiopulmonary resuscitation at PCI initiation.
Methods From October 2005 through September 2007, PCI was performed during 29,784 admissions in Massachusetts
nonfederal hospitals. Of these, 5,588 involved patients with ST-segment elevation myocardial infarction or car-
diogenic shock. Cases with CU criteria identified were adjudicated by trained physician reviewers. Regression
models with and without the CU composite variable (presence of any of the 3 features) were compared using
areas under the receiver-operator characteristic curves.
Results Unadjusted mortality in this high-risk subset was 5.7%. Among these admissions, 96 (1.7%) had at least 1 CU fea-
ture, with 69.8% mortality. The adjusted odds ratio for in-hospital death for CU PCIs (vs. no CU criteria) was 27.3 (95%
confidence interval: 14.5 to 47.6). Discrimination of the model improved after including CU, with areas under the
receiver-operating characteristic curves increasing from 0.87 to 0.90 (p  0.01), while goodness of fit was preserved.
Conclusions A small proportion of patients at extreme risk of post-PCI mortality can be identified using pre-procedural factors
not routinely collected, but that heighten predictive accuracy. Such improvements in model performance may
result in greater confidence in reporting of risk-adjusted PCI outcomes. (J Am Coll Cardiol 2011;57:904–11)
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performed within the state and to provide rigorous statistical
assessments of any differences in the risk-adjusted mortality
among hospitals and individual PCI operators. The Massa-
chusetts program uses Bayesian hierarchical logistic regression
models to evaluate the quality of cardiac care as assessed by the
in-hospital, risk-adjusted, all-cause mortality after PCI (1).
he hierarchical model methodology has been shown to be
ore specific in the detection of performance outliers than
onhierarchical methods (2,3).
See page 912
The public release of risk-adjusted mortality reports is
controversial (4–8) and can have a significant impact on the
hospitals and operators through adverse publicity associated
with being identified as a negative outlier in quality perfor-
ance (8). From the outset of the PCI reporting effort, the
assachusetts program actively engaged interventional cardi-
logists in the case review and adjudication process for all
atients with high-risk clinical features. In addition, clinicians
ere directly involved in the process of developing the risk-
rediction models, based on the covariates available in the
ational Cardiovascular Data Registry (NCDR) CathPCI
egistry (version 3.04) in an effort to establish the maximum
onfidence by the clinical community in the risk-adjustment
ethodology. Based on physician input, Massachusetts di-
ided the population of patients undergoing PCI into 2 groups:
hose presenting with ST-segment elevation myocardial infarc-
ion (STEMI) or cardiogenic shock (the shock or STEMI or
OS group), and all other, typically less acute PCI admissions
non-SOS group).
Although the NCDR CathPCI Registry dataset is
roadly used as a quality monitoring tool throughout the
.S., it had not been originally intended for nor designed to
e applied to mandatory public reporting as used in Mas-
achusetts. Recognizing limitations in the breadth of the
ariables collected in the existing CathPCI Registry dataset,
nterventional cardiologists in Massachusetts became con-
erned that the risk-adjustment models were limited in their
bility to account fully for the clinical acuity of the most
ritically ill patients. There was a specific concern that
linicians could become increasingly risk averse due to fears
hat the risk-model methodology would not adequately
djust for the highest risk patient populations being treated.
he concerns centered on the possibility that uncaptured
and thus unmodeled) covariates, such as impaired neuro-
ogic status on presentation, might be independently pre-
ictive of in-hospital mortality. Exclusion of such poten-
ially strong, independent predictors of mortality that could
ary in prevalence across hospitals would reduce the clinical
redibility of the models and might lead to inaccurate
rediction of post-PCI mortality.
The concerns raised by Massachusetts clinicians wereased, in part, on the observation that there had been agradual decrease in the propor-
tion of patients treated with PCI
for cardiogenic shock in New
York in the years since that state
began publishing reports of
clinician-specific risk-adjusted
outcomes (4). Supporting this
view, several surveys of New
York State PCI operators and
cardiac surgeons indicated an in-
creasing unwillingness to treat
the most severely ill patients after
the introduction of public report-
ing of mortality outcomes, de-
spite validated risk-adjustment
models (7). Moreover, it had
been observed that New York
interventionalists and cardiac surgeons were unique among
geographic locales in providing lower rates of revasculariza-
tion for patients included in a national cardiogenic shock
registry (9), despite mounting evidence of the clinical
benefits of early revascularization of most patients present-
ing in cardiogenic shock (10). In 2008, New York State
began excluding patients presenting in cardiogenic shock
from the publicly released risk-adjusted mortality reports. In
light of these findings, clinical advisors to the Massachusetts
public reporting program recommended inclusion of addi-
tional high-risk clinical factors not routinely collected in the
CathPCI Registry dataset in an effort to improve the
performance of the risk-adjustment models as well as to
bolster clinician acceptance of the risk-adjustment process.
We sought to examine the feasibility of collecting a set of
novel factors likely predictive of post-PCI demise and their
impact in the Massachusetts risk-adjusted models of in-
hospital mortality.
Methods
Patient and hospital populations. We studied all patients
age 18 years or older presenting with cardiogenic shock or
STEMI and who underwent PCI at any of the Massachu-
setts, nonfederal, acute care hospitals between October 1,
2005, and September 30, 2007. Because it was possible for
patients to undergo 1 PCI during a single admission, we
selected the first PCI as the unit of observation in accor-
dance with NCDR risk adjustment methods and to reflect
the clinical status of the patient on presentation. Patients
were assigned to the hospital where the initial PCI was
performed, even if transferred elsewhere for subsequent
procedures.
Data sources. We used clinical and billing data submitted
to the Massachusetts Data Analysis Center (Mass-DAC),
the data coordinating center located in Harvard Medical
School under contract with the Department of Public
Health of the Commonwealth of Massachusetts to collect,
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft
CU  compassionate use
Mass-DAC 
Massachusetts Data
Analysis Center
NCDR  National
Cardiovascular Data
Registry
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarctionclean, and analyze the PCI data. Three distinct data sources
m
t
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mation obtained during the hospital admission was col-
lected prospectively by trained data managers using variables
defined in the NCDR CathPCI Registry dataset (American
College of Cardiology, 2010) and submitted electronically
every 3 months. Massachusetts hospitals were also man-
dated by regulation to supplement the NCDR data with
additional elements incorporating patient identification in-
formation and details regarding the identity of hospitals
from which and to which patients may have been trans-
ferred. To ensure completeness of the admissions submitted
to Mass-DAC, inpatient discharge billing data available
from the Division of Health Care Finance and Policy in the
Massachusetts Department of Public Health were linked to
the Mass-DAC data using patient and hospital identifiers.
The billing data included patient demographic information,
as well as diagnoses and procedures performed during the
hospitalization. Finally, while data managers report patient
vital status at discharge, Mass-DAC confirmed this infor-
mation by linking to the Massachusetts Registry of Vital
Records and Statistics.
Compassionate use. Beginning October 1, 2005, Mass-
DAC added 3 unique covariates to those available in the
NCDR CathPCI dataset and collected this information
electronically at regular intervals. The new covariates were
termed “compassionate use” (CU) criteria and were in-
tended to identify extremely high risk clinical scenarios not
currently characterized by the existing NCDR data instru-
Definition of Compassionate Use CriteriaTable 1 Definition of Compassionate Use Criteria
Criteria Definition Notes
Coma on
presentation
The patient presents to the
emergency department
or the cardiac
catheterization
laboratory with a
Glasgow Coma Scale
score of 7 and is
coded as emergent
status.
The coma must not be
medication induced.
Use of ventricular
assist device
The medical record must
indicate the use of CPB,
ECMO, or PVAD before
the start of the PCI.
Use of ventricular support
must be justified in the
medical record.
Use of CPB/ECMO or
PVAD to rescue a
diagnostic case
complication would
not be a criterion for
compassionate use.
CPR at start of
procedure
The medical record must
reflect that spontaneous
circulation was not
restored before the start
of the PCI, and,
therefore, the patient
was receiving active
CPR at the start of
the PCI
Excludes patients
successfully
resuscitated in the
field without the need
for ongoing CPR.
Using CPR to rescue a
diagnostic case
complication would
not be a criterion for
compassionate use.
CPB  cardiopulmonary bypass; CPR  cardiopulmonary resuscitation; ECMO  extracorporeal
embrane oxygenation; PCI  percutaneous coronary intervention; PVAD  percutaneous ven-
ricular assist device.ment. The CU criteria included coma on presentation for
emergent PCI, use of a percutaneous ventricular assist
device or extracorporeal bypass, and cardiopulmonary resus-
citation at the initiation of the procedure. Of note, both
coma on presentation and cardiopulmonary resuscitation at
initiation of the procedure required that the case also be
coded as an emergent or salvage procedure, whereas a
planned or emergent ventricular assist device–supported
procedure would also qualify as CU. Table 1 summarizes
the definitions of the additional CU covariates.
All CU cases were independently reviewed, adjudicated,
and confirmed by physician reviewers trained in the defini-
tions of items in the NCDR data instrument (e.g., cardio-
genic shock, PCI status as emergent or salvage) as well as
the CU criteria. All reviewers underwent training in re-
search on human subjects and were approved by the Har-
vard Medical School’s Institutional Review Board. The CU
case adjudication process scrutinized every case coded as CU
using supplemental clinical documentation forwarded to
Mass-DAC. This documentation included emergency de-
partment and emergency medical services records (when
appropriate), cardiac catheterization laboratory reports, and
clinical documentation for the inpatient hospital course. If a
physician reviewer was uncertain about a particular adjudi-
cation, the case was discussed with the other members of the
review committee, and a decision was reached by consensus.
An appeal process was established so that medical centers
could challenge the adjudication of any particular case that
was originally ruled to not meet the CU criteria. All appeals
required additional clinical documentation explicitly justify-
ing the use of CU designation. Appeal adjudications were
made by board-certified interventional cardiologists with
extensive experience in the adjudication process.
Primary outcome. The primary patient outcome was mor-
tality, regardless of cause, during the hospitalization (or out-
patient procedure, if applicable) in which the PCI was per-
formed. Secondary outcomes included survival at 30 days and
12 months, as assessed by linked data analysis with Massachu-
setts death index, and assessment of impact of inclusion of CU
adjustment on hospital quality classification.
Statistical analysis. Univariate analyses were performed
using the chi-square test, or the Fisher exact test was
implemented using SAS version 9 (SAS Institute, Cary,
North Carolina) (11). Hierarchical logistic-normal regres-
sion models that included random hospital-specific inter-
cepts were used to account for within-hospital clustering
and estimated using the WinBUGS application (12). The
CU covariate was operationalized as a binary composite
variable that assumed a value of 1 if any of the specified
conditions was observed to be true; otherwise, it assumed a
value of 0. In-hospital mortality prediction models were
developed using hierarchical regression models, including
and excluding the compassionate use covariate.
The discriminating ability of the model was assessed by
the area under the receiver-operating characteristic curve.
We calculated the difference in the area under the receiver-
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without the CU variables using a paired test (13). Because
we were also interested in how the addition of the variables
would affect risk prediction, we undertook a reclassification
analysis to assess the proportion of patients whose predicted
mortality changed by at least 1 quintile of risk (14). This was
accomplished by calculating the risk quintile for each
patient using both the predictive model excluding and
including the compassionate risk covariate. The Net Reclas-
sification Improvement measure that reflects the overall gain
in prediction due to the inclusion of the compassionate use
covariate was also calculated (15).
Results
Between October 1, 2005, and September 30, 2007, at least
1 PCI occurred in a total of 29,784 admissions in Massa-
chusetts licensed (nonfederal) hospitals. Among these ad-
missions, 5,588 patients (18.8%) underwent a PCI after
presenting with shock or STEMI (SOS cases). Within this
SOS cohort of patients, a total of 96 patients (1.7% of SOS
cases) were adjudicated as having qualified for CU.
CU admissions were significantly more likely to have pre-
sented in cardiogenic shock (Table 2) (65.6% vs. 8.2%, p 
.001), more likely to have received an intra-aortic balloon
ump (49.0% vs. 12.5%, p  0.001), and more likely to have
re-existing renal insufficiency on presentation (15.6% vs.
.1%, p  0.001) compared with SOS patients without CU
linical features.
In-hospital outcomes for CU patients were dramatically
orse than for the high-risk SOS cohort of patients without
U clinical features as a whole (Table 3). The likelihood of
rocedural success was significantly lower for CU patients
ompared with non-CU SOS patients (79.2% vs. 94.2%,
ContinuedTable 2 Continued
Characteristic
Compassionate
Use
All, n (%) p Value*No Yes
STEMI 5,175 180 5,255 (94) 0.00015
No STEMI 317 16 333 (6)
Status of PCI
Elective/urgent 332 333 (6) 0.00001
Emergent 5,143 60 5,203 (93)
Salvage 17 35 52 (1)
LMCA lesion 268 76 5,300 (95) 0.00001
No LMCA lesion 5,224 20 288 (5.2)
Intra-aortic balloon pump 652 47 699 (13) 0.00001
No intra-aortic balloon
pump
4,840 49 4,889 (87)
Successful procedure 5,176 76 5,252 (94) 0.00001
Unsuccessful procedure 316 20 336 (6)
*All p values use the Fisher exact test with the exception of race, ejection fraction, and
percutaneous coronary intervention status, which use chi-square tests.
CABG coronary artery bypass graft; CHF congestive heart failure; LMCA left main coronary
artery; LVEF  left ventricular myocardial infarction; MI myocardial infarction; PCI  percutane-
us coronary intervention; STEMI  ST-segment elevation myocardial infarction.Patient Presenting Factors in the Cardiogenic Shockor ST-Segment Myoc rdial Infarction PCI Cohort,Overall and Stratified by Compassionate Use
Table 2
Patient Presenting Factors in the Cardiogenic Shock
or ST-Segment Myocardial Infarction PCI Cohort,
Overall and Stratified by Compassionate Use
Characteristic
Compassionate
Use
All, n (%) p Value*No Yes
No. of admissions 5,492 96 5,588
Female 1,587 32 1,619 (29) 0.364
Male 3,905 64 3,969 (71)
Age, yrs
60 2,813 37 2,850 (51) 0.11
61–70 1,127 25 1,152 (21)
71–80 976 22 998 (18)
80 576 12 588 (11)
Race
White 4,816 77 4,893 (88) 0.10
African American 140 3 143 (2.6)
Hispanic 161 5 166 (3.0)
Other 346 11 357 (6.4)
Previous MI 937 24 961 (17) 0.055
No previous MI 4,555 72 4,627 (83)
Diabetes mellitus 1,097 33 1,130 (20) 0.0012
No diabetes mellitus 4,395 63 4,458 (80)
History of renal failure 226 15 241 (4) 0.00001
No history of renal failure 5,266 81 5,347 (96)
History of CHF 311 14 325 (5.8) 0.0012
No history of CHF 5,181 82 5,263 (94)
Cerebrovascular disease 374 17 391 (7) 0.0003
No cerebrovascular
disease
5,118 79 5,197 (93)
Peripheral vascular
disease
482 17 499 (9) 0.0057
No peripheral vascular
disease
5,010 79 5,089 (91)
Chronic lung disease 586 16 602 (11) 0.0672
No chronic lung disease 4,906 80 4,986 (89)
Hypertension 3,354 58 3,412 (61) 0.9161
No hypertension 2,138 38 2,176 (39)
Current smoker 2,059 33 2,092 (37) 0.5952
Not a current smoker 3,433 63 3,496 (63)
Dyslipidemia 3,478 48 3,526 (63) 0.0101
No dyslipidemia 2,013 48 2,061 (37)
Previous PCI 813 9 822 (15) 0.1479
No previous PCI 4,679 87 4,766 (850)
Previous CABG 248 10 258 (5) 0.0126
No previous CABG 5,244 86 5,330 (95)
Current CHF 834 48 882 (16) 0.00001
No current CHF 4,658 48 4,706 (84)
Renal failure/dialysis 39 4 43 (1) 0.0060
No renal failure/dialysis 5,453 92 5,545 (99)
LVEF
Not measured 2,858 53 2,911 (52) 0.00001
30% 433 25 458 (8.2)
31% and 40% 510 8 518 (9.3)
40% 1,691 10 1,701 (30)
Cardiogenic shock 394 63 457 (8) 0.00001
No cardiogenic shock 5,098 33 5,131 (92) 0.001). The CU patients were significantly more likely
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more likely to experience bleeding and renal complications
after the index procedure than non-CU patients. The
unadjusted in-hospital mortality rate was 15.6 times higher
for CU patients than for non-CU SOS patients (69.8% vs.
4.5%, p  0.001). Although CU patients represented only
1.7% of overall SOS patients, these patients accounted for
more than 21% of the overall mortality after PCI in the SOS
cohort. Post-procedure death from neurological causes was
significantly more frequent in the CU population compared
with the standard-risk SOS patients, likely driven by the
concentration of patients presenting with coma in the CU
cohort. The observed mortality for CU patients with use of
percutaneous ventricular support, resuscitation at the start of
the procedure, and coma on presentation were 50%, 84%,
and 70% respectively. Due to the relatively small individual
sample sizes, there was no significant difference in the
mortality rates between these 3 categories.
After adjusting for all other known predictors of in-
hospital mortality, CU designation was associated with an
odds ratio for in-hospital death of 27.3 (95% confidence
interval: 14.5 to 47.6) relative to the non-CU SOS patients.
The final multiple logistic regression model included patient
In-Hospital Complications and Death,Overall and Stratified by Compassionate UseTable 3 In-Hospi al Complicat s and Death,Overall and Stratified by Compassionate Use
Complication
Compassionate
Use
All, n (%) p Value*No Yes
No. of admissions 5,492 96 5,588
New cardiogenic shock 148 6 154 (3) 0.0484
No new cardiogenic shock 5,344 90 5,434 (97)
New renal failure 68 7 75 (1) 0.00027
No new renal failure 5,424 89 5,513 (99)
Any bleeding complication 417 14 431 (8) 0.0185
No bleeding complication 5,075 82 5,157 (92)
Any vascular complication 48 2 50 (1) 0.2118
No vascular complication 5,444 94 5,538 (99)
Any vascular or bleeding
complication
447 15 462 (8) 0.0139
No vascular or bleeding
complication
5,045 81 5,126 (92)
Blood products used 643 25 668 (12) 0.00017
No blood products used 4849 71 4,920 (88)
In-hospital survival 5247 29 5276 (94) 0.00001
In-hospital death 245 67 312 (6)
Cause of in-hospital death
(n  312)
Cardiac 185 46 231 (74) 0.21
Neurological 12 15 27 (9)
Renal 3 0 3 (1)
Vascular 1 1 2 (1)
Infection 9 0 9 (3)
Pulmonary 16 3 19 (6)
Other/unknown 19 2 21 (7)
*All p values use the Fisher exact test, with the exception of cause of death, which is based on a
chi-square test.age, pre-procedure renal insufficiency, documented pre-procedure left ventricular ejection fraction 30%, emergent
or salvage procedure status, presence of left main coronary
artery disease (of severity 50%), presentation with cardio-
genic shock, and the CU indicator (Table 4).
Among those CU patients who survived to hospital
discharge, 83% (24 of 29) were alive at 30 days, whereas
76% (22 of 29) were alive at 1 year.
Inclusion of the CU covariates significantly improved the
in-hospital mortality risk prediction model performance.
The discrimination of the hierarchical mortality prediction
model significantly improved from an area under the
receiver-operating characteristic of 0.87 to 0.90 (p  0.001)
with preserved goodness of fit. Individual cases were as-
signed to 5 risk strata according to predicted risk before and
after incorporation of CU criteria. Incorporation of the CU
covariate led to the reclassification of the risk by at least 1
risk stratum for 347 SOS patients (6.2%). The net reclas-
sification improvement was 8.7% (p 0.43), indicating that
8.7% more patients who died appropriately moved up a
category of risk than down compared with survivors. Most
of the impact of inclusion of the new covariate was observed
for those who died during the hospitalization (Fig. 1).
In this analysis, overall classification of hospital perfor-
mance did not change significantly with the inclusion of the
CU indicator variable (Fig. 2). However, there were mea-
surable changes in the width and range of the estimated
posterior intervals, which made certain centers “closer” to a
change in classification as an outlier institution. For exam-
ple, the posterior interval for hospital 1 was shifted to the
left after including the CU indicator, indicating a reclassi-
fication of cases, which results in improved estimated quality
relative to the overall state performance, as compared with
the method that excluded the CU indicator. In contrast, the
posterior interval estimate for hospital 12 was shifted to the
right after inclusion of the CU indicator, indicating that
reclassification of cases resulted in a less favorable estimate
Adjusted Odds Ratios of Risk of In-Hospitalll-Cause Mortality After PCI in theCommonwealth of Massachuset s*
Table 4
Adjus ed Odds Ratio of Risk of In-Hospital
All-Cause Mortality After PCI in the
Commonwealth of Massachusetts*
Risk Factor
Compassionate Use
Excluded
Compassionate Use
Included
Adjusted
Odds
Ratio
95% Posterior
Interval
Adjusted
Odds
Ratio
95% Posterior
Interval
Age, yrs
60–70 1.47 (0.97–2.15) 1.66 (1.04–2.50)
70–80 2.48 (1.68–3.57) 2.94 (1.90–4.30)
80 5.37 (3.63–7.65) 6.90 (4.49–10.1)
Renal insufficiency 3.19 (2.10–4.64) 3.11 (2.01–4.58)
Ejection fraction 30% 1.74 (1.12–2.57) 1.64 (1.02–2.46)
Presence of LMCA lesion 1.94 (1.29–2.83) 1.73 (1.09–2.55)
Emergent or salvage PCI 2.51 (1.23–4.42) 2.06 (1.09–3.69)
Cardiogenic shock 14.0 (10.6–18.4) 9.91 (7.07–13.4)
Compassionate use Excluded 27.28 (14.5–47.6)*Based on 5,588 PCI admissions from October 2005 through September 2007 and 312 deaths.
Abbreviations as in Table 2.
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12 was closer to being identified as an outlier for poorer
performance after incorporation of CU indicators than for
the models that did not include CU. However, there were
no changes in the posterior interval estimates that led to a
change in overall classification by institution as either above,
below, or within expectations for risk-adjusted mortality,
although the observed changes in posterior intervals con-
firms the potential impact of the inclusion of CU indicators
on assessment of hospital quality.
Although the impact on physician perception of the
risk-adjustment methods was not directly measured in this
study, a temporal association was apparent after the intro-
duction of the CU indicator in October 2005, with a
substantial increase in the prevalence of cardiogenic shock
among PCI admissions (Fig. 3). The proportion of overall
PCI patients presenting in cardiogenic shock monotonically
decreased from 2.3% in 2003 to 1.3% in 2005. Beginning
with the inclusion of CU criteria in late 2005, this trend
reversed, with an increasing proportion of patients treated
with PCI for cardiogenic shock for both 2006 and 2007 to
a level of 1.7%. Of note, there was no concomitant change
to the risk-adjustment methodologies used for predicting
Figure 1 Impact of Inclusion of CU on Predicted Mortality in
5,588 PCI Patients With Shock or STEMI
Impact of inclusion of compassionate use (CU) indicator on predicted mortality for
patients in the high-risk (cardiogenic shock or ST-elevation myocardial infarction
[STEMI]) cohort. The horizontal axis represents the predicted mortality excluding
CU, whereas the vertical axis represents predicted mortality after inclusion of the
CU indicator covariate. The diagonal line indicates no change in predicted mortality
for individual cases. The patients with CU features had significant increases in
their predicted mortality, which further discriminated patients who survived versus
those who were an in-hospital fatality. PCI  percutaneous coronary infarction.mortality after coronary artery bypass graft (CABG) sur-gery, and the proportion of CABG cases with shock has
declined steadily since the inception of public reporting of
post-revascularization outcomes (Fig. 3).
Discussion
The Massachusetts experience demonstrates that a small
proportion of patients at extremely high risk of in-hospital
mortality can be identified using objective, pre-procedure
clinical factors that had not been previously collected as part
of traditional quality monitoring efforts. Incorporation of
these CU covariates in risk-adjustment models led to
significant improvements in model performance as well as
reclassification of predicted risk in a substantial proportion
of cases. The NCDR dataset was supplemented with CU
covariates without significant changes in data collection
methods, and these additional variables predictive of mor-
tality were conducive to comprehensive case-level review
and adjudication.
In Massachusetts between 2005 and 2007, CU patients
represented 1.72% of all high-risk cardiogenic shock or
STEMI patients, with an in-hospital mortality rate of
69.8% (vs. 4.45% for other shock or STEMI patients). The
adjusted odds ratio for CU was 27.3 (95% confidence
interval: 14.5 to 47.6) compared with the non-CU shock or
STEMI patients. Nearly two thirds of CU patients were
already coded as presenting in cardiogenic shock, indicating
the extreme instability of these CU patients on arrival to the
cardiac catheterization laboratory. Importantly, the presence
Figure 2 Hospital Risk-Adjusted Mortality
With and Without CU Variable
Posterior mean risk-standardized mortality rates and corresponding 95% inter-
vals (x axis) for each Massachusetts hospital (y axis) based on a hierarchical
model excluding the compassionate use (CU) variable (solid red line) and on a
hierarchical model including the CU variable (dashed green line).
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tive of in-hospital mortality, conferring substantial addi-
tional risk of in-hospital death beyond that of cardiogenic
shock alone. Despite a prevalence of CU criteria in only
1.7% of the analyzed cohort, the inclusion of the covariate
significantly improved model discrimination and risk
prediction.
Beyond improving the performance of the risk-prediction
models, the incorporation of CU covariates was intended to
increase the confidence of participating physicians in the
risk-adjustment methodology used in Massachusetts. Al-
though the potential association between inclusion of the
CU covariate and changes in physician willingness to treat
high-risk patients with PCI cannot be directly inferred from
the available data, the observed change in proportion of
patients treated for cardiogenic shock (Fig. 3) may indicate
a positive influence on physician acceptance of the risk-
adjustment methodology.
There was debate within the medical and regulatory com-
munities in Massachusetts as to the best approach to handling
cases identified as CU. Although many physicians advocated
excluding such cases altogether from the risk-prediction mod-
els, the regulator community held that CU was an appropri-
ately “behaved” predictor variable for in-hospital mortality,
which added to the discrimination of the prediction models
and should therefore be included in the final model. The
current study confirms the utility of including CU as an
independent predictor of in-hospital mortality, and the tem-
poral association of inclusion of CU in the model with the
increasing proportion of the sickest patients in cardiogenic
Figure 3 Emergent Revascularization for Cardiogenic Shock in
Temporal trends of the prevalence of treatment for cardiogenic shock for both the
bypass graft (CABG) (blue bars) cohorts in Massachusetts, 2003–2007. The red a
tor covariates in the PCI mortality prediction models. There was no change in the
prevalence of cardiogenic shock as an indication for PCI is noted to be temporallyshock being treated with PCI may demonstrate a physicianacceptance of the improvement of modeling performance and,
therefore, patient selection behavior.
The generalizability of incorporation of CU variables into
voluntary PCI registries such as the NCDR CathPCI
registry hinges on the accuracy of institutionally reported
CU status compared with the central adjudication process
used in Massachusetts. In the first year of use of the CU
criteria, 69 cases were coded by the participating hospitals as
CU, of which 49 (71%) were adjudicated as meeting criteria
for CU. This proportion of adjudication rejection for a
high-risk clinical factor is similar to the Massachusetts
experience for the institutional coding of cardiogenic shock
and may therefore be representative of the accuracy of
institutionally reported high-risk features. Therefore, it
appears that incorporation of CU in a voluntary registry may
be reasonable, given the current reliance on noncentrally
adjudicated high-risk factors with similar adjudication re-
jection rates.
Study limitations. This analysis was based on clinical data
from a mandatory statewide observational registry with a
well-publicized and rigorous audit program, and its gener-
alizability is therefore limited. Specifically, each fatal, high-
risk, and CU case was individually reviewed and key
variables adjudicated by volunteer practicing interventional
cardiologists trained in use of definitions from both the
NCDR data instrument and the CU variables, resulting in
high credibility of the final dataset. However, not all PCI
cases and not all variables in the risk prediction models
could be uniformly reviewed. Post-PCI mortality occurring
achusetts, 2003–2007
taneous coronary intervention (PCI) (red bars) and isolated coronary artery
indicates the time of introduction of the compassionate use (Comp Use) indica-
ediction methodology for isolated CABG during the study period. A change in the
iated with the introduction of the compassionate use indicator covariate.Mass
percu
rrow
risk pr
assocafter transfer to another facility was also not evaluated.
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February 22, 2011:904–11 Compassionate Use Improves PCI Risk PredictionConclusions
The incorporation of CU covariates in a statewide clinical out-
comes registry is feasible, significantly improves mortality risk
prediction model performance, and was temporally associated
with an increase in the prevalence of cardiogenic shock among
patients undergoing PCI in Massachusetts. Improvements to risk
model performance with regard to extremely high-risk patients
may provide clinicians, regulators, and health care consumers with
increased confidence regarding the results of mandatory public
reporting of risk-adjusted PCI outcomes.
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